Cancer Archives

News and Trends 25 Jun 2015

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Personalized medicine is the next thing and immunotherapy expert BioNTech is determined to build its place in this competitive field. With this purpose in mind, the German biotech will partner with Siemens to build a new production plant for personalized cancer vaccines. Founded in 2008, the BioNTech Group has become one of the fastest-growing biotechnology […]

June 25, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 19 Jun 2015

Servier disburses €114 Million for Taiho’s Colorectal Cancer treatment

Servier is fattening up its oncology assests with the acquisition of Taiho Pharmaceutical’s treatment of refractory mestatic colorectal cancer. The French laboratories will commercialize the molecule in Europe and other countries. Taiho Pharmaceutical and Servier come to an agreement for the development and commercialization of TAS-102 in Europe. The drug is an oral combination anticancer drug […]

June 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Jun 2015

Innovate UK accelerates Sareum’s fight against Leukemia

Innovate UK, the country’s innovation agency, keeps promoting technology in the British islands. The latest beneficiary is Sareum, a cancer specialist biotech with a strong autoimmune disease programme. The company received €195.5k to fight an early-age type of leukaemia. T-Cell Acute Lymphoblastic Leukaemia is a rare type of leukaemia that most often occurs in late […]

June 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jun 2015

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

Genmab and its partner Jonhson&Jonhson, through its subsidiary Janssen Biotech, are trying to speed up daratumumab. The companies initiated a rolling submission for the candidate that targets multiple myeloma. The German-American partnership is trying to accelerate the arrival of daratumumab to the market, only just after the presentation of optimistic results of MOR202’s phase I/IIa. […]

June 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Jun 2015

Polaris, a new Nordic leader in Immuno-Oncology

Immuno-oncology is a busy market to take on by yourself due to the existing fierce competition. Targovax and Oncos Therapeutics have decided to merge to earn a spot in the field. Polaris, the combined business, contemplates a private placement of around €15M to fund the freshly baked company. Finland and Norway never were this close as Oncos […]

June 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Jun 2015

French collaboration to develop Oncology-targeted Therapy

PEP-Therapy and CleveXel Pharma will co-develop targeted therapy in oncology. The product is based on an innovative technology involving bi-functional peptides that penetrate cells, and specifically block pathological mechanisms without affecting physiological mechanisms. The drug candidate is a cell-penetrating peptide that targets an interaction between two intracellular proteins, Caspase-9 and PP2A. It has been validated […]

June 10, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 Jun 2015

NuCana’s potent anti-cancer completed Phase I/II

Good news just keeps on coming from ASCO Annual Meeting. Edinburgh-based NuCana presented in two abstracts the last data from Acelarin, the company’s first anti-cancer agent, produced on its ProTide developing platform. ProTides are NuCana’s new class of anti-cancer agents, which are specifically designed to overcome key cancer resistance mechanisms that severely limit the action […]

June 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

MorphoSys has presented at ASCO optimistic results of MOR202’s phase I/IIa study, a candidate treatment against multiple myeloma. The project was doubted after Celgene’s abandon, but now, safety and efficacy data have shown that there is nothing to worry about. MOR202 is a fully human monoclonal HuCAL antibody targeting CD38, a highly expressed and validated target […]

June 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

[Update] AstraZeneca to buy a CAR-T expert?

[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca’s CEO Pascal Soriot. The CEO was not talking about the specific acquisition of Juno Therapeutics but about a potential acquisition of a CAR-T expert. Juno’s shares rose as much as 15.8 % just after the rumor was released by Bloomerg. Here is the first version […]

June 4, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 3 Jun 2015

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). Erytech Pharma’s technology makes it possible to “starve” cancer cells by depriving them of […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002’s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform. Vaxiclase is a technology platform that can be used with many antigens in several […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Immuno-oncology has gone from a competition to a battlefield. Bristol-Meyer Squibb launched a lawsuit against David Berman, a former researcher that abruptly quit last month after 10 years working for the company’s cancer R&D division. Berman, with his deep knowledge about BMS’s immune-oncology research, headed to AstraZeneca, BMS’ principal opponent. Game on. In this competitive […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

BioNTech and Siemens to build a new Production plant for Personalized Cancer Vaccines

Servier disburses €114 Million for Taiho’s Colorectal Cancer treatment

Innovate UK accelerates Sareum’s fight against Leukemia

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

Polaris, a new Nordic leader in Immuno-Oncology

French collaboration to develop Oncology-targeted Therapy

NuCana’s potent anti-cancer completed Phase I/II

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

[Update] AstraZeneca to buy a CAR-T expert?

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!